First Keystone Corporation (FKYS) YTD Net Income Rises 39.9% to $9.48M

First Keystone Corporation (FKYS) reported YTD net income of $9.48M, up 39.9% YoY, with EPS of $1.50 and dividends of $0.84. Assets reached $1.73B, and deposits increased $123.30M as of Sep 30, 2026.

Original reporting
Published Oct 30, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
First Keystone Corporation (FKYS) YTD Net Income Rises 39.9% to $9.48M — source image
Decision brief

The 30-second read

$FKYSBullishLow
01

Why it matters

The disclosed earnings improvement provides a modest catalyst for short‑term price movement but limited longer‑term upside without sustained NIM growth.

02

Market read

Company‑specific earnings news with low trading relevance for broader markets.

03

What to watch

Potential future pressure from core NIM expansion needs and credit quality monitoring.

Relevance 5/10Novelty 5/10Timing: after-hours

Background

First Keystone Corporation is a small regional bank; the YTD figures reflect a mid‑cycle profitability rebound aided by reserve releases.

Company-level read

Ticker impact

$FKYSBullishMedium confidence
Context

First Keystone reported YTD net income up 39.9% to $9.48M, the first disclosure of these earnings figures.

Expected impact

likely slight upside as market prices in the earnings improvement

Evidence & confidence

The earnings beat is new information but the absolute profit size is small for a micro‑cap, limiting impact.

Market effects

Minimal effect on the regional banking sector; earnings beat is company‑specific.

Limited to investors in micro‑cap banking stocks.

None

Counterpoint

The earnings beat may be overstated if reserve releases are one‑time, so price could stall.

Key entities

  • First Keystone Corporation

    Regional bank reporting YTD earnings.

Related articles

$FKYSMed

FIRST KEYSTONE ANNOUNCES THIRD QUARTER 2026 EARNINGS (UNAUDITED)

FIRST KEYSTONE CORP (FKYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FIRST KEYSTONE ANNOUNCES THIRD QUARTER 2026 EARNINGS (UNAUDITED) ​ Berwick, Pennsylvania – October 30, 2026 - First Keystone Corporation (OTCID: FKYS), parent company of First Keystone Community Bank, reported an increase in total interest income of $3,195,000 or 5.6

$FKYSLow

FIRST KEYSTONE ANNOUNCES SECOND QUARTER 2026 EARNINGS (UNAUDITED)

FIRST KEYSTONE CORP (FKYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FIRST KEYSTONE ANNOUNCES SECOND QUARTER 2026 EARNINGS (UNAUDITED) ​ Berwick, Pennsylvania – July 30, 2026 - First Keystone Corporation (OTCID: FKYS), parent company of First Keystone Community Bank, reported an increase in total interest income of $2,124,000 or 5.7%,

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

HighAI 8/10

Merck KGaA Earnings Call Signals Stronger Growth Ahead

Merck KGaA (MKKGY) reported Q3 earnings with accelerated growth, raised full-year guidance, and announced strategic investments. Key highlights include 5.1% organic sales growth, EUR 1.66B operating cash flow, and plans to acquire Silence Therapeutics. Management emphasized growth in biomanufacturing, semiconductors, and rare diseases, while noting Mavenclad's declining sales and softer demand in consumer electronics.